AstraZeneca
What Science Can Do
About AstraZeneca
Funding & Growth
✓ Pros
- • Strong oncology pipeline
- • Growing presence in US (Gaithersburg, Boston)
- • Investment in AI/ML
- • Diverse therapeutic areas
- • Good benefits
✗ Cons
- • UK headquarters (timezone)
- • Large company bureaucracy
- • Some integration challenges
- • Geographic spread of teams
🏢 Working Here
AstraZeneca operates major US computational biology centers in Boston, MA (R&D Centre housing ~300 scientists), Gaithersburg, MD (US headquarters), and South San Francisco, CA, alongside global headquarters in Cambridge, UK.
The Boston R&D Centre focuses on immuno-oncology, human genetics, and early discovery, making it a key global site for computational biology.
Located near Kendall Square, it provides direct access to Dana-Farber, Mass General, Brigham and Women's Hospital, plus collaborations with MIT and Broad Institute.
AZ transformed into an oncology powerhouse with Tagrisso (lung cancer, >$5B revenue), Lynparza (PARP inhibitor), and Imfinzi (checkpoint inhibitor).
The culture emphasizes 'Follow the Science', bold innovation, and patient focus.
AZ invested massively in genomics including a 2 million participant genetics initiative for target discovery.
Work involves analyzing tumor samples from clinical trials, integrating population-scale genetics with functional genomics, and developing combination therapy biomarkers.
The Boston location specifically drives immuno-oncology innovation and attracts top computational talent given the city's cancer research concentration.
🧬 Bioinformatics Focus
AZ's computational biology emphasizes oncology and human genetics. Core areas:
- Oncology precision medicine - analyzing samples from Tagrisso, Lynparza, Imfinzi trials, developing predictive biomarkers, understanding resistance mechanisms for targeted and immuno-therapies,
- Immuno - oncology - analyzing tumor immune infiltration, predicting checkpoint inhibitor response, developing biomarkers for combinations,
- Human genetics at scale - 2M participant genetics initiative for target validation, statistical genetics methods for rare variants, multi-ancestry GWAS,
- Cardiovascular and metabolic diseases - genetics of heart failure, chronic kidney disease, diabetes, identifying novel targets,
- Respiratory diseases - asthma and COPD genetics and multi-omics, biologics biomarker development. AZ pioneered industrial-scale genetics for drug discovery and maintains partnerships with academic biobanks globally. The company has published extensively including high-impact papers on genetic target validation and cancer biomarkers. Technical challenges include integrating genetics across 2M participants from diverse ancestries, analyzing complex tumor microenvironments, and developing combination therapy biomarkers (many AZ trials combine 2-3 agents).
📈 Career Growth & Development
Career Paths
Scientist Track
Leadership Track
Compensation
Compensation in US locations is competitive with 15-20% target bonuses and stock options. The Boston location commands premium pay.
Development
AstraZeneca emphasizes continuous learning through extensive training programs including data science and AI bootcamps. Publications are strongly encouraged in journals like Nature, Cell, and NEJM.
Mobility
Internal mobility between US and UK sites is supported, though UK roles may require work authorization.
Culture
AstraZeneca's resurgence as an oncology leader has created a growth culture with continued investment in computational biology.
Expertise
Many computational biologists specialize in cancer genomics, immuno-oncology, or genetics. The 2M genetics initiative creates unique expertise in large-scale genetics.
Growth
Recent successes, like Tagrisso revenue exceeding $5B, ensure continued investment in computational biology and career growth.
💊 Top Medicines & Blockbuster Drugs
Tagrisso (osimertinib)
2015Indication: EGFR-mutated non-small cell lung cancer
3rd-gen EGFR TKI - first-line and resistance setting
Annual Revenue (USD)
Farxiga (dapagliflozin)
2014Indication: Type 2 diabetes, heart failure, chronic kidney disease
SGLT2 inhibitor - cardiovascular/renal benefits
Annual Revenue (USD)
Imfinzi (durvalumab)
2017Indication: Non-small cell lung cancer, small cell lung cancer, bladder cancer
PD-L1 checkpoint inhibitor
Annual Revenue (USD)
Lynparza (olaparib)
2014Indication: BRCA-mutated ovarian, breast, pancreatic, prostate cancers
First-in-class PARP inhibitor (Merck partnership)
Annual Revenue (USD)
Calquence (acalabrutinib)
2017Indication: Chronic lymphocytic leukemia, mantle cell lymphoma
Next-gen BTK inhibitor - better tolerability
Annual Revenue (USD)